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Abstract. Cyclic constraints are incorporated here into an 11-residue analogue of the N-terminus of glucagon-like 
peptide-1 (GLP-1) to investigate effects of structure on agonist activity. Cyclization through linking side chains of 
residues 2 and 5 or 5 and 9 produced agonists at nM concentrations in a cAMP assay.  2D-NMR and CD spectra re-
vealed an N-terminal β-turn and a C-terminal helix that differentially influenced affinity and agonist potency. These 
structures can inform development of small molecule agonists of the GLP-1 receptor to treat type 2 diabetes. 
Type 2 diabetes is one of the greatest impending 
global health burdens that already affects >350 million 
people, but is projected to increase to ~600 million by 
2035.1 Glucagon-like peptide-1 (GLP-1) is a naturally 
occurring hormone that potentiates glucose-dependent 
insulin secretion from the pancreas while stimulating 
proliferation and inhibiting apoptosis of pancreatic β-
cells.2 It also inhibits food intake and gastric emptying 
leading to weight loss.3 Current treatments for T2D in-
clude injectable peptide analogues of full-length GLP-
1(7-36)-NH
2 
(HAEGTFTSDVSS-YLEGQAAKEFIA-
WLVKGR-NH
2
),4 and oral inhibitors of dipeptidyl pep-
tidase IV that protect GLP-1 from cleavage of two resi-
dues from its N-terminus.5 Small molecule oral GLP-1 
agonists remain elusive.6  
The interaction of GLP-1 with its receptor can be 
partially rationalized as follows. The GLP-1 receptor 
(GLP-1R) is a G protein-coupled receptor found on 
pancreatic islets and other cells that captures the helical 
C-terminal half (bolded above) of GLP-1 and presents 
the N-terminal half (italicized above) in an unknown 
manner to activating residues in the receptor.7 The re-
cently solved crystal structure of the closely related glu-
cagon receptor was used in conjunction with previously 
reported mutation studies to propose a binding model 
for glucagon which shows the first 5 five residues in a 
flexible conformation binding in a deep binding pocket 
within the seven trans membrane region of the struc-
ture, whilst residues from S8 onwards are in an alpha 
helical conformation.8 The proposed binding model also 
suggests a turn type motif between residues 4 and 7.8 
Removing the two N-terminal residues (His-Ala) or 
more than 3 C-terminal residues of GLP-1(7-36)-NH
2
 
attenuated activity.9 
The most successful downsizing of GLP-1 is a series 
of 11 amino acids peptides (Scheme 1) bearing bulky 
hydrophobic substituents (X) at positions 6, 10 and 11 
which potently activate GLP-1R.10-11 
 
 
Scheme 1. Eleven residue peptides (1a, 1b) that acti-
vate GLP-1R. 
The most successful downsizing of GLP-1 is a series 
of 11 amino acids peptides (Scheme 1) bearing bulky 
hydrophobic substituents (X) at positions 6, 10 and 11 
which potently activate GLP-1R.10-11 
Here we report biophysical (NMR) and computational 
guided design studies to produce novel cyclized vari-
ants of 11-mer peptide 1a which in turn may inform the 
 design of small, orally available GLP-1R agonists.   The 
NMR-derived helical structure of 1a was determined 
under conditions (25 mM SDS-d
25
 in H
2
O) that simulate 
to some extent a water-membrane environment (Fig. 
1A) that may be relevant for the binding of 1a to the 
membrane-spanning GLP-1R. VT-NMR data (Δδ/T ≤ 4 
ppb/K) and NOE correlations (dαN(i,i+3), dαN(i,i+4)) supported some 
helical structure between residues 4-11 (Fig. 2A). N-
terminal residues 1-3 were disordered but stronger dαN(i,i+2) 
than dαN(i,i+4) NOEs in this region suggested a turn confor-
mation. The Cα…Cα distance (6.1 Å) between residue 5 
and residue 9 was typical of an α-helix (idealized α-helix 
= 6.1 Å, idealized 3
10
-helix = 8.3 Å). A reported NMR 
structure for 1a in aq dimethyl sulfoxide (1:3 
H
2
O:DMSO-d
6
) suggested instead that residues 6-11 may 
adopt an elongated (3
10
) helix.10 We therefore also deter-
mined an NMR structure for 1a in 1:3 H
2
O:DMSO-d
6
 
(Fig. 1B). Under these conditions we found a slightly 
elongated α-helix between C-terminal residues 6-11, 
with the average Cα…Cα distance between residues 6 
and 10 being 6.3 Å, while the Thr5 Cα … Cα Aib2 sepa-
ration was 5.6 Å - consistent with a β-turn structure at 
the N-terminus. These findings prompted us to insert 
cyclization constraints into the sequence to stabilize an 
α-helix between residues 6-11 or a β-turn at residues 2-
5, and to investigate the possible influences of these 
structural motifs on agonist activity mediated by human 
GLP-1R. 
 
Figure 1. Backbone superimposition of 10 lowest energy 
refined NMR structures of 1a in: (A) 25 mM SDS-d
25
 in wa-
ter and (B): H
2
O:DMSO-d
6
 (1:3). Magenta ribbons show ave 
peptide backbone structures. Arrows show ave Cα-Cα dis-
tances between residues 5-9 (6.1 Å) and 2-5 (5.6 Å). 
Connecting the side chains of residues 5 and 9 in 
compound 1b produced analogues 2-6, each with a cy-
clic constraint of variable ring size at the C-terminus 
(Table 1). In a cyclic pentapeptide, the linker corre-
sponding to that in 2 is known12 to enforce more α-
helicity than any lactams used in 3-6. Constraining the 
11mer peptide with any of these lactam-bridged linkers 
reduced binding affinity and cAMP activity relative to 
1a and 1b. However, 2 (EC
50
 59 nM) and 3 (EC
50 
17 nM) 
retained appreciable agonist potency. The Lys5→Glu9 
lactam bridge in 3 typically11 promotes a more loosely 
constrained helix. Expanding the cycle by an additional 
methylene group through substituting homoglutamate 
for Glu9 (4) further loosened the constraint but sub-
stantially reduced agonist potency. Swapping the lac-
tam forming residues in the two most potent com-
pounds (2 and 3) substantially reduced cAMP activity (5 
and 6, respectively), supporting the importance of the 
location of the lactam and/or helical structure in this 
segment. Alanine mutagenesis studies have shown that 
the 9th residue (Asp15) in GLP-1 is crucial for cAMP ac-
tivity, with complete loss of activity and 40-fold reduc-
tion in binding affinity after Asp15Ala substitution.13 On 
the other hand the 5th residue (Thr11) was found to be 
less critical for binding (13-fold reduction) and agonist 
activity (2-fold reduction).13 Compounds 2-6 displayed 
poor competitive binding with GLP-1, but competed 
effectively with a labelled analogue of 1. While lactam 3 
was less potent than 1b, the efficacy obtained was bet-
ter than expected from the Ala mutations in GLP-1. In 
general, the trend in affinity for this series of 11-mer 
ligands correlated with cAMP activity (Table 1). How-
ever, the Ki/EC
50
 ratio (Fig. S1) was lower for lactams 2, 
3 and 6 (0.51-0.87) than for 1a and 1b (ratio 3.5-4.6). 
This suggests that agonism of the lactams is more af-
finity driven than for the unconstrained peptides, per-
haps due to the loss of Glu9. The most potent cyclic 
compound 3 was analysed for structure by CD and 2D-
NMR spectroscopy. 
 
Figure 2. 1H-NMR NOE summary for 1a (1 mM): (A) in 25 
mM SDS-d
25
 in H
2
O:D
2
O (9:1) and (B) in H
2
O:DMSO-d
6
 (1:3). 
Sequential and medium range NOEs, bar thickness corre-
sponds to strong (< 2.7 Å), medium (<3.5 Å), weak (<5.0 Å) 
or very weak (<6.0 Å) NOE intensities. Overlapping cross-
peaks (gray bars). Amide NH temperature coefficients 
(Δδ/T) ≤ 4 ppb/K (•). 
A second series of compounds (7-16, Table 1) incor-
porated a cyclization constraint between residues 2-5. 
NMR derived structures (Fig. 1B) and computer model-
ing studies (Fig. S2, supporting information) indicated 
that Thr5 and Aib2 were in close proximity and part of 
a β-turn structural motif. The distance between the α-
carbons of Aib and Thr5 suggested that a linker of 4-6 
heavy atoms in length might imprint a matching β-turn. 
Alanine mutagenesis on GLP-1 has shown that residues 
 2 and 5 may be altered without substantial effects on 
binding or cAMP function, although substituting Ala2 
with Ser reduced binding by 9-fold without greatly af-
fecting cAMP12.  The orientation of Aib in Fig. 1B and 
S2 showed that both stereoisomers were tolerated, but 
with a preference for the natural configuration at Thr5. 
Compounds with a cysteine-cysteine or a cysteine-
homo cysteine linker (7-12) were found to bind hGLP-
1R with low affinity (IC
50
 > 400nM) and exhibited only 
moderate to weak cAMP activity (EC
50
 80-700 nM). Link-
ing homocysteines at residues 2 and 5, with either LL or 
DL stereochemistry (13 or 14), improved binding affini-
ty and cAMP activity, but LD or DD stereochemistry (15 
or 16) reduced cAMP activity (EC
50
 >200 nM) and bind-
ing affinity (IC
50
 > 1000 nM), consistent with the predict-
ed geometry preference. The Ki/EC
50
 ratio (Fig. S1) was 
higher for disulfides 12-14 (44-75) than for uncon-
strained peptides 1a-1b (ratio 3.5-4.6). This suggests 
that agonism of the disulfides is more efficacy driven 
than for the unconstrained 11mers, perhaps due to sta-
bilization of a bound N-terminal turn conformation. 
Compound 14 was selected for solution structure anal-
ysis by NMR and CD spectra. 
 
Figure 3. CD spectra of 1a (black), 2 (pink), 3 (red), 14 
(blue)
 
at 50 µM (298 K) in (A): 10 mM aq phosphate (pH 
7.2); (B): aq 10 mM SDS. 
Circular dichroism spectra were compared to assess 
relative helicity in 1a, 2, 3 and 14 in water vs an aq lipid 
environment (Fig. 3). Compound 1a was unstructured 
in water (Fig. 3A, black), but became slightly helical in 
aq. 10 mM SDS (Fig. 3B, black) where the lineshape 
(ratio θ
222
 : θ
208
 < 0.5) is consistent with some turn charac-
ter, as suggested for the N-terminus by NMR data (Fig. 
1A, 2A). In contrast, the CD spectrum for 2 in water 
(Fig. 3A, pink) showed a molar ellipticity maximum 
(197 nm) and two minima (222, 208 nm; ratio 1:1), in-
dicative of a highly α-helical structure. The CD spectra 
for 3 and 14 had very weak intensity bands in water 
(Fig. 3A, red and blue respectively), consistent with 
more turn-like structure. However 3 was more helix-
like in aq SDS (Fig. 3B, red), while 14 changed little 
with positive molar ellipticity attributed to D-
homocysteine at position 2 (Fig. 3B, blue). Given high 
affinities and agonist potencies for 3 and 14, we decid-
ed to use NMR spectroscopy to more closely examine 
their solution structures. 
The NMR-derived solution structure for 3 in 
H
2
O:DMSO-d
6
 (1:3) is shown below (Fig. 4). As expected 
from above, there was evidence of distinct helical struc-
ture between residues 3 to 10, with a more flexible N-
terminus. The presence of dαN(i,i+3) and dαN(i,i+4)  along with dNN(i,i+1) 
and 
 
dαβ(i,i+3) suggested the structure is alpha helical for the 
peptide in this solvent mixture. 
Table 1: Affinity and agonist potency, on human GLP-
1R transfected in CHO cells, of 15 derivatives of 1b 
incorporating a side chain to side chain cyclisation 
restraint between positions 2→5 or 5→9. 
 Linkera  
in 1b 
analogues 
Affinityb,c 
Ki, nM 
n 
cAMPc,d 
EC
50, 
nM 
n 
1a - 0.66 (0.17) 6 0.19 (0.019) 31 
1b - 0.57 (0.86) 8 0.12 (0.024) 13 
2 Lys5-Asp9 59 (24) 3 68 (24) 5 
3 Lys5-Glu9 17 (5.5) 8 10 (2.3) 6 
4 Lys5-hGlu9 300 (60) 3 95 (25) 5 
5 Asp5-Lys9 1200 (120) 3 320 (130) 4 
6 Glu5-Lys9 320 (70) 8 430 (180) 5 
7 Cys2-Cys5 >3100 6 670 (140) 10 
8 cys2-Cys5 2400 (310) 3 600 (54) 4 
9 Cys2-hCys5 980 (430) 5 190 (34) 3 
10 cys2-hCys5 550 (210) 4 81 (27) 5 
11 hCys2-Cys5 >8000 7 730 (200) 5 
12 hcys2-Cys5 4800 (640) 3 110 (39) 4 
13 hCys2-
hCys5 
130 (120) 8 1.8 (0.79) 4 
14 hcys2-
hCys5 
41 (13) 3 0.73 (0.18) 7 
15 hCys2-
hcys5 
3000 (600) 3 390 (90) 3 
16 hcys2-
hcys5 
1700 (280) 3 200 (27) 3 
aLys, lysine; Asp, aspartate; Glu, glutamate; hGlu, 
homoglutamate; Cys, cysteine; cys, D-cysteine; hCys, ho-
mocysteine; hcys, homo-D-cysteine. Number = sequence 
position in 1b. bCompetitive binding vs 18 (Supp Material). 
cGeometric	   mean with standard error in parentheses. 
dcAMP was measured in CHO cells stably transfected with 
human GLP-1R (Supp Material; all compounds were full 
agonists relative to GLP-1 (85-107%). For compounds 2- 
16, X
6
 = αMe-2F-Phe, X
10
 = Bip, X
11
 = hhPhe.  Fig. S3 shows 
representative cAMP response curves for 1a, 3 and 14. 
An NMR-derived solution structure was also calculat-
ed for 14 in H
2
O:DMSO-d
6
 (1:3) (Fig. 5), which is the 
most potent agonist in the second series. At the N-
terminus, crosslinking residues 2 and 5 via coupling D-
homocysteine to L-homocysteine side chains restrained 
 the cyclic tetrapeptide segment (hc-E-G-hC) into a type 
II β-turn conformation, as revealed by the dαN(i,i+2) NOEs 
observed in this region. The average Cα…Cα distance 
between residues 2 and 5 in these NMR structures is 5.5 
Å. This is very similar to the average corresponding 
distances (5.6 Å) found for the unconstrained peptide 
1b in H
2
O:DMSO-d
6
 (1:3). At the C-terminus, there were 
small 3J
NHH
α amide coupling constants, medium intensity 
d
NN(i,i+1)
 and dαN(i,i+1) NOEs, and stronger dαN(i,i+2) intensities com-
pared to dαN(i,i+3) with unobservable dαN(i,i+4) NOEs for residues 
6-10. This data supports an elongated helical structure 
rather than a more compact α-helix for the C-terminus 
of 14. The average Cα…Cα distance between residues 6 
and 10 was 7.0 Å instead of 6.1 Å in an α-helix and 8.3 
Å for a 3
10
-helix. 
 
Figure 4. NMR structure summary for 3 (1 mM) in 
H
2
O:DMSO-d
6
 (1:3) at 298 K. (Top): 1H-NMR data summary 
showing sequential and medium range NOEs, with bar 
thickness proportional to strong (upper distance constraint 
2.7 Å), medium (3.5Å), weak (5.0 Å) and very weak (6.0 Å). 
3J
NHCHa
 ≤ 6 Hz (↓) NOE intensities. (Bottom): Backbone super-
imposition from residues 1-11 of 20 lowest energy refined 
structures (peptide side chains omitted for clarity; carbon, 
green; nitrogen, blue; hydrogen, white; oxygen, red; lactam 
bridge K5-E9, gray). X6 = αMe-2F-Phe, X10 = biphenyl, 
X11= hhPhe. 
The two structural motifs identified in Figure 1, from 
the NMR structures determined for the ‘linear’ peptide 
1b in different solvent mixtures, were superimposed 
(Fig. 6) upon the corresponding cyclization-constrained 
sections of compounds 3 and 14. The results show that 
constraining the peptide through an optimized cycliza-
tion linker between residues 2 and 5 has produced a 
beta turn backbone segment in 14 that matches the 
turn structure observed for the acyclic peptide 1b in aq 
DMSO solvent (Fig. 6A). Further, the alpha helix struc-
ture observed by NMR spectroscopy for 1b in aq. SDS 
NMR is mimicked by the helix-constrained analogue 3 
(Fig. 6B). 
 
Figure 5. NMR structure summary for 14 (1 mM) in 
H
2
O:DMSO-d
6
 (1:3) at 298 K. (Top): 1H-NMR summary show-
ing sequential and medium range NOEs, bar thickness 
proportional to strong (upper distance constraint 2.7 Å), 
medium (3.5 Å), weak (5.0 Å) and very weak (6.0 Å) NOE 
intensities. 3JNHCHa ≤ 6 Hz (↓) and broad singlet (*) (Bot-
tom): Backbone superimposition from residues 5-10 of ten 
lowest energy refined structures (peptide side chains omit-
ted for clarity; carbon, green; nitrogen, blue; hydrogen, 
white; oxygen, red; disulfide bridge hc2-hC5, gray). X6 = 
αMe-2F-Phe, X10 = biphenyl, X11= hhPhe. 
By combining these two important structural features 
(type II β-turn and α-helix) derived from the con-
strained peptide analogues 14 and 3, we created a com-
bined topology map of Cα-Cβ bond vectors of the side 
chains of those amino acid residues that were most in-
fluential in determining agonist activity (Fig. 6C). This 
map could serve as a guide for further development of 
peptidomimetics with β-turn and α-helix mainchain 
motifs and as a pharmacophore map of sidechain vec-
tors for future development of small molecule agonists 
for GLP-1R. 
  
Figure 6. Combination of N-terminal β-turn (from 14) and 
C-terminal α-helix (from 3) compared with 1a (orange). (A): 
Superimposed backbone residues 1-5 from NMR-derived 
structures of peptides 1a and 14 superimposed in 
H2O:DMSO-d6 (1:3). Ave RMSD = 1.92 Å. (B): Superim-
posed backbone residues 5-11 from NMR-derived struc-
tures of peptides 1a and 3 in 25 mM SDS-d
25
/water. Aver-
age RMSD = 0.40 Å. (C): Cα-Cβ vector topologies (arrows) 
for side chains of residues important for agonist activity. 
Peptide side chains omitted for clarity; carbon, green; ni-
trogen, blue; hydrogen, white; oxygen, red; disulfide 
bridge in (A) and lactam bridge in (B), gray. X2 = hcys and 
X5 = hCys (in 14). X5 = Lys and X9 = Glu (in 3). X6 = αMe-
2F-Phe. X10 = biphenyl. X11 = hhPhe. Vector coordinates 
in C along with all 4 structures (Figs. 1, 4, 5) were lodged 
in a publicly accessible structural database.14 
Conclusions. 
Solution structures were determined for a potent 
GLP-1R agonist 1 in aq SDS versus aq DMSO solvent 
mixtures using NMR spectroscopy. They revealed two 
dominant structural motifs; a helical structure between 
residues 5-9 and a turn structure between residues 2-5. 
Constraining residues 5-9, using a series of lactam 
bridges designed to alter the nature and flexibility of 
the helix, reduced agonist potency and binding affinity. 
The most potent lactam-constrained compound 3 did 
not contain the most α-helical structure, but it was only 
slightly elongated. CD spectra supported this finding, 
while the NMR structure revealed that the dominant 
structure was still mainly α-helical. The other dominant 
structural feature in 1 from NMR studies was mimicked 
in compounds 13 and 14 with potent cAMP activity and 
high receptor-binding affinity. The NMR structure of 
compound 14 revealed a type II β-turn between amino 
acids 2-5, with some elongated α-helical character re-
tained between positions 6-10. These data provide im-
portant lessons for developing improved GLP-1 ago-
nists.  The helical structure, stabilized with lactams over 
residues 5-9, diminished efficacy more than affinity. By 
contrast, stabilization of a β-turn, using a disulfide 
crosslink over residues 2-5, diminished affinity more 
than efficacy. These differential effects of the structural 
constraints on potency vs affinity of GLP-1 agonists 
(Fig. S1) has helped to identify important structural 
requirements and limitations for activity of pep-
tidomimetic and small molecule agonists for the type 2 
diabetes target GLP-1R. 
E XP E R IM E N TA L   
Chemicals. See Supporting Information. Peptide 
Synthesis. Peptides were synthesized by standard Fmoc 
chemistry methods described elsewhere.12 Lactam bridg-
es where formed as described previously.12. Disulfide 
bridge formation: The crude linear peptide (just cleaved 
from resin) was dissolved in water.  To the resulting 
aqueous solution, iodine in methanol (20 mg/mL) was 
added until a brown solution was afforded.  Full syn-
thetic details are provided in the SI. Purification of 
Peptides. Crude peptides (pellets) were dissolved in a 
minimal amount of water and purified using a Waters 
4000 system connected to a Waters Delta-PakTMC18, 
15 micron, 100 Å reversed-phase HPLC column  (25 x 
200 mm) eluting with a solvent gradient of A and B 
where solvent A was 0.1% TFA in water and solvent B 
was 0.1% TFA in acetonitrile:water (4:1)].  The specific 
gradient conditions are described for final peptides. 
(SI) Purified peptides were analyzed to confirm >95% purity 
using an HP1090 system with a 4.6 x 150 mm SepaxGP- C18 
(2), 5 micron, 120 Å column or a 4.6 x 150 mm Phenomenex 
C18 (2), 5 micron 100 Å column eluting with a solvent gradi-
ent of A and C, where solvent A was 0.1% TFA in water and 
solvent C was 0.09% TFA in acetonitrile:water (4:1), over 20 
minutes at a flow rate of 1.0 mL/min. The specific retention 
times, UV purities (220 nm), and solvent gradients are de-
scribed for final peptides in the SI.  
Radioligand Binding Assay. The ability of test com-
pounds to displace a 125I-labeled 11 amino acid GLP-1R 
agonist (compound 18) was performed. Compound af-
finity was expressed as a K
i
 value, defined as the con-
centration of compound required to decrease 18 bind-
ing by 50% for a specific membrane batch at a given 
concentration of radioligand. The non-radiolabelled 
analogue of 18 had Ki = 6.0 (2.7) nM for binding affinity 
and EC
50
= 0.045 (0.013) nM for cAMP. Full experimental 
details are provided in the SI.  
CHO cAMP Accumulation Assay. CHO cells stably 
transfected with hGLP-1R were incubated (37 °C, 95% 
O
2
, 5% CO
2
) in flasks containing DMEM/F12 (1:1) media 
supplemented with 1% GlutaMAX™(Gibco®), 1% Pen-
Strep and 1% Geneticin® (Gibco®). Following LANCE® 
 Ultra cAMP assay (Perkin Elmer) manufacturers in-
structions, cells were washed (PBS), lifted (cell dissocia-
tion solution), centrifuged (1500 rpm, 5 minutes), re-
suspended in cAMP assay buffer (HBSS, 5.56 mM glu-
cose, 0.1% BSA (final), 0.5 mM IBMX (final), 5 mM 
HEPES (final)) and seeded (1000 cells/well) in a Prox-
iPlate-384 Plus plate (Perkin Elmer). Cells were treated 
with compounds (10 µM - 100 fM) diluted in assay buff-
er at room temp for 30 minutes. Cell lysis buffer plus 
Tracer (1:50) or Ulight (1:150) (supplied in cAMP assay 
kit) were added to each well and incubated covered at 
room temp for 2 h before plate was read on a 
PHERAstar FS (BMG Labtech). For analysis, com-
pound raw signal was normalised to a percentage of 
GLP-1 maximum raw signal.  
CD measurements: were performed using a Jasco 
model J-710 spectropolarimeter as previously decribed, 
full experimental details are described in the SI. 
NMR Spectroscopy and Structure Calculations: Full 
experimental details are provided in the SI. 
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tide-1; GLP-1R, GLP-1 receptor; hC, homocysteine, 
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acid; VT. Variable temperature; DMEM, Dulbecco's Modi-
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